Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rusal considers closing unprofitable plants

10/17/23 RUAL

State Duma in the 1st reading allowed Novatek to export LNG without a link to fields

10/17/23 NVTK

Board of Directors of Rostelecom recommended that dividends be paid for 2022

10/17/23 RTKM

Renaissance Insurance reported for 9 months of 2023 by RAS

10/17/23 RENI

State Duma approved in the second reading the export of LNG from Rosneft's Arctic fields

10/17/23 ROSN

Yakovlev may conduct additional issue for 32 billion shares

10/17/23 IRKT

Goldman Sachs announced a quarterly dividend

10/17/23 GS

Goldman Sachs reported for 9 months of 2023

10/17/23 GS

Government supported the split of Transneft shares

10/17/23 TRNFP

Bank of America reported for 9 months of 2023

10/17/23 BAC